The week in prescription drug pricing: what moved, what it means for patients, and what comes next.
In an exclusive first reported by The Hill, P4ADNow and AARP sent a joint letter to top House committee leaders urging them to reject the EPIC Act (H.R. 1492) — a pharmaceutical industry-backed bill…
News Apr 25, 2025A major new poll from Republican polling firm Fabrizio Ward confirms what patients have long known: Voters overwhelmingly support bold action to lower drug prices, and their views are driven by their lived experiences.
News Apr 18, 2025President Trump’s new executive order (EO) on drug pricing proposes a sweeping change to the Medicare negotiation program that would delay negotiations for small-molecule drugs, typically lower-cost pills, by four years.
News Apr 11, 2025Despite President Trump’s decision to pause broad-based tariffs on most countries, concerns are mounting as he continues to double down on potential pharmaceutical tariffs — a move that would drive…
News Apr 4, 2025P4AD launched a new national TV ad this week, airing on Fox & Friends, urging President Trump to continue defending Medicare’s ability to negotiate lower drug prices and deliver a better deal for American patients.
News Mar 28, 2025President Trump confirmed this week that pharmaceutical tariffs remain on the table as part of a broader trade package.
News Mar 21, 2025The Centers for Medicare and Medicaid Service (CMS) has announced that all 12 manufacturers of the 15 drugs selected for the second round of the Medicare negotiation program have voluntarily agreed to participate.
News Mar 14, 2025Big Pharma has spent decades exploiting loopholes in the patent system to extend monopolies, block competition, and keep drug prices high.
News Mar 7, 2025Senators Bernie Sanders and Ron Wyden, Ranking Members of the Senate HELP and Senate Finance Committees, respectively, reintroduced a health package that includes key bipartisan reforms to lower drug…
News Feb 28, 2025This week, Patients For Affordable Drugs (P4AD) filed an amicus brief in the Third Circuit Court of Appeals, defending Medicare’s ability to negotiate lower drug prices against a lawsuit brought by Novartis.
